- Home
- SU vs TAK Comparison
SU vs TAK Comparison
Compare SU & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SU
- TAK
- Stock Information
- Founded
- SU 1917
- TAK 1781
- Country
- SU Canada
- TAK Japan
- Employees
- SU N/A
- TAK N/A
- Industry
- SU Integrated oil Companies
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- SU Energy
- TAK Health Care
- Exchange
- SU Nasdaq
- TAK Nasdaq
- Market Cap
- SU N/A
- TAK 47.0B
- IPO Year
- SU N/A
- TAK N/A
- Fundamental
- Price
- SU $34.25
- TAK $14.29
- Analyst Decision
- SU Buy
- TAK
- Analyst Count
- SU 5
- TAK 0
- Target Price
- SU $57.00
- TAK N/A
- AVG Volume (30 Days)
- SU 4.8M
- TAK 1.9M
- Earning Date
- SU 05-06-2025
- TAK 05-08-2025
- Dividend Yield
- SU 4.70%
- TAK 4.11%
- EPS Growth
- SU N/A
- TAK 15.39
- EPS
- SU 3.36
- TAK 0.83
- Revenue
- SU $35,225,240,881.00
- TAK $29,124,927,177.00
- Revenue This Year
- SU N/A
- TAK $8.66
- Revenue Next Year
- SU N/A
- TAK N/A
- P/E Ratio
- SU $10.20
- TAK $34.09
- Revenue Growth
- SU 2.16
- TAK 9.83
- 52 Week Low
- SU $30.79
- TAK $12.58
- 52 Week High
- SU $41.95
- TAK $15.37
- Technical
- Relative Strength Index (RSI)
- SU 43.43
- TAK 38.68
- Support Level
- SU $33.50
- TAK $15.01
- Resistance Level
- SU $36.34
- TAK $15.43
- Average True Range (ATR)
- SU 0.82
- TAK 0.19
- MACD
- SU 0.01
- TAK -0.05
- Stochastic Oscillator
- SU 26.41
- TAK 6.17
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.